We are live on ! Find out more
MGRX icon

Mangoceuticals
MGRX

1 hedge funds and large institutions have $5.32K invested in Mangoceuticals in 2023 Q1 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

0.03% more ownership

Funds ownership: 0% → 0.03% (+0.03%)

Holders
1
Holders Change
+1
Holders Change %
–
% of All Funds
0.02%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
UBS Group
UBS Group
Switzerland
+$11K

Top Sellers

No sellers this quarter

MGRX Hedge Fund Activity: Q1 2023 in Review

1 of the 6,285 institutional investors tracked by Wall St. Rank reported a position in Mangoceuticals (MGRX) for Q1 2023, worth a combined $5.32K.

Buyers outnumbered sellers: 1 fund opened new MGRX positions and 0 closed out — a net gain of 1 holder — while 0 added to existing stakes and 0 trimmed.

The largest buyer was UBS Group, opening a new position worth an estimated $11K.

  • 1 institutional investor held Mangoceuticals (MGRX) as of Q1 2023, up from 0 in Q4 2022.
  • Funds reported $5.32K of Mangoceuticals stock for Q1 2023.
  • 1 fund opened new Mangoceuticals positions in Q1 2023 and 0 closed out, a net change of +1 holder.
  • The largest Mangoceuticals buyer in Q1 2023 was UBS Group, an estimated $11K added.

Based on aggregated 13F filings for Q1 2023.